Efficacy and Safety of Argatroban and Bivalirudin in Patients with Suspected Heparin-Induced Thrombocytopenia

Annals of Pharmacotherapy - Tập 49 Số 2 - Trang 178-184 - 2015
Quynh-Anh T. Vo1, Joyce K. Lin2,3, Lisa M. Tong4,5
1Quynh-Anh T. Vo, PharmD, BCPS, at time of writing, PGY-1 Pharmacy Practice Resident, Veterans Affairs Medical Center, San Francisco, CA
2Assistant Clinical Professor of Pharmacy, University of California at San Francisco
3Joyce K. Lin, PharmD, CACP, BCACP, Anticoagulation Clinical Pharmacist, Veterans Affairs Medical Center, San Francisco, CA; Assistant Clinical Professor of Pharmacy, University of California at San Francisco
4Associate Clinical Professor of Pharmacy, University of California at San Francisco
5Lisa M. Tong, PharmD, CACP, Anticoagulation Clinical Pharmacist, Veterans Affairs Medical Center, San Francisco, CA; Associate Clinical Professor of Pharmacy, University of California at San Francisco

Tóm tắt

Background: Argatroban is the only commercially available Food and Drug Administration (FDA)–approved anticoagulant for managing heparin-induced thrombocytopenia (HIT). However, bivalirudin may be an attractive alternative. Objective: To assess the efficacy and safety of argatroban and bivalirudin in patients with suspected HIT. Methods: This single-center, retrospective analysis included patients who received argatroban or bivalirudin for at least 24 hours between January 1, 2000, and June 30, 2012. The primary end point assessed anticoagulation goals, specifically time to therapeutic activated partial thromboplastin time (aPTT) goal and percentage of aPTT values within therapeutic range. Secondary end points included new thromboembolic events, bleeding, and mortality. Results: Of the 68 patients who met the inclusion criteria, 48 received argatroban and 20 received bivalirudin. Baseline characteristics were similar between the 2 groups except for age, percentage of patients with liver dysfunction, aPTT immediately prior to drug initiation, and the serotonin release assay results. The mean ± SD times to reach therapeutic aPTT goal for argatroban and bivalirudin were 14 ± 15 and 7 ± 8 hours, respectively ( P = 0.024). The mean ± SD percentage of aPTT values within therapeutic aPTT goal was 69% ± 23% for argatroban and 84% ± 18% for bivalirudin ( P = 0.005). Rates of thromboembolic events were similar between the 2 groups, as were the rates of bleeding and all-cause mortality. Conclusions: Bivalirudin appears to reach therapeutic aPTT goal faster with more aPTT values within therapeutic aPTT goal while achieving similar clinical outcomes. Although not approved by the FDA for managing HIT, bivalirudin may be an attractive alternative anticoagulant.

Từ khóa


Tài liệu tham khảo

10.1080/09537109975960

10.1182/blood-2005-04-1546

10.1378/chest.11-2303

Refludan (lepirudin) [product information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; 2010.

Argatroban (argatroban) [product information]. Research Triangle Park, NC: GlaxoSmithKline; 2012.

Orgaran (danaparoid) [product information]. West Orange, NJ: Organon Inc; 1998.

Mayo Clinic. Danaparoid (subcutaneous route). http://www.mayoclinic.com/health/drug-information/DR600517. Accessed July 25, 2013.

US Department of Health and Human Services Health Resources and Service Information. http://www.hrsa.gov/opa/programrequirements/manufacturerletters/2012/refludan05312012.pdf. May 2012.

Francis J, 2003, Blood, 102, 164a

10.1592/phco.26.4.461

10.1592/phco.28.9.1115

10.1592/phco.30.12.1229

10.1345/aph.1Q177

10.1592/phco.31.9.850

Angiomax (bivalirudin) [package insert]. Parsippany, NJ: Medicines Company; 2012.

10.1309/D79K4YG78NTNYY38

10.1001/archinte.163.15.1849

10.1592/phco.2005.25.12.1736

10.2165/00002018-200932030-00003

10.1161/01.CIR.103.14.1838

10.1111/j.1538-7836.2005.01623.x

Thông tin
Thông tin xuất bản

Annals of Pharmacotherapy

Tập 49 Số 2

178-184

Thông tin tác giả